Will the two pharmaceutical stocks Yifangda have the risk of exit?

Zhongxin Jingwei, September 26 (Xue Yufei) According to the data disclosed by the Hong Kong Stock Exchange website, E Fund Fund Management Co., Ltd. (hereinafter referred to as Yifangda) recently increased its shareholding in Haijia Medical. By September 22, 2022 The number increased to 372.722 million shares, accounting for 6.04%of the issued shares of the issuance. Just two days ago, on September 20, Yi Fangda had just increased its holdings of Rongchang Biopharmaceutical, accounting for 6.16%of the shares with the right to vote.

Earlier, the Nuoan Fund had "raised" A shares Zhuo Shengwei, which attracted attention. What is the intention of Yifangda's two pharmaceutical stocks? Will there be the risk of exit?

The market value of holding shares reaches HK $ 1.6 billion

According to the equity disclosure information of the Hong Kong Stock Exchange website, Yifangda has recently increased the shares of Hygia Medical. First of all, on September 14, E Fund's shares held by Hygia Medical increased to 30.9746 million shares, accounting for 5.02%of the shares with the right to vote, achieving "lifting cards". On September 22, Yifangda increased the number of shares to 37.272 million, and the share ratio rose to 6.04%.

Perhaps due to the influence of the good news of the agency's holdings, Hygia Medical's stock price increased by 4.56%on the 26th, and the closing price was 44.75 Hong Kong dollars per share. Based on this calculation, the market value of Yifangda's holding of Hygia Medical stocks reached approximately HK $ 1.668 billion. As for which funds that are in E Fund, it is unknown for increasing Hergia Medical Stocks. However, as of the end of the second quarter of 2022, the scale of funds managed by Chen Hao and Zhang Kun was high.

According to Wind data, as of the end of the second quarter, a total of 13 fund companies with 13 fund companies held Haijia Medical stocks. E Fund's holdings had the highest holdings, reaching 12.9162 million shares, accounting for 2.09%of circulating stocks. Among them, the growth of Yifangda Hong Kong Stock Connect (holding 4.54 million shares), the future of Yifangda Innovation (holding 4.2354 million shares), and the growth of balanced growth (holding 4.1408 million shares) in the top three The growth of the Hong Kong Stock Connect increased slightly in the second quarter of this year. The other two funds were bought in the second quarter. The managers of these three funds are Chen Hao.

According to the second quarter of the 2022 report, the Blue Chip managed by Zhang Kun disclosed that as of the end of the second quarter, the fund held 5.5 million shares of Hygia Medical. In addition, as of the end of the second quarter, the Yifangda Pharmaceutical Bio managed by Yang Yanxiao also held the company's 10.63 million shares.

Rongchang Biopharmaceutical is also "lifted"

In addition to Hygia Medical, according to the website of the Hong Kong Stock Exchange, Yifangda increased its holdings of Rongchang Biopharmaceutical in the second quarter. On March 23, 2022, Yifangda's shares holding Rongchang Biopharmaceuticals accounted for 5%of the issued shares with the right to vote. By May 20, it dropped slightly to 4.92%.

On July 8, 2022, the number of Yifangda held Rongchang Biopharmaceutical's shares increased to approximately 9.777 million shares, accounting for 5.11%of the issued shares with the right to vote, and once again achieved "campaign". The number of shares increased to approximately 11.687 million shares, with a share ratio of 6.16%. According to the closing price of 37.35 Hong Kong dollars/share on the 26th, E Fund's market value of Rongchang Biopharmaceutical Stocks was approximately HK $ 436 million.

Rongchang Biopharmaceutical, which increases its holdings of Yifangda, needs data disclosure of fund products. According to Wind data, as of the end of the second quarter, Yang Yanxiao's Yifunda Pharmaceuticals held 2.3335 million shares of Rongchang Biopharmaceuticals, accounting for about 1.23%of circulating stocks.

Not only these two pharmaceutical stocks, on January 4, 2022, Yi Fangda "raised" the Great Wall Motor, accounting for 5.03%of the shares with the right to vote. By March 21, the shareholding data fell to about 153 million shares, the proportion fell to 4.95%, and it was only a "lifting card". According to the closing price of HK $ 10.14/share on the 26th, the market value of Yifangda holding Great Wall Motor's stock was approximately HK $ 1.554 billion.

Yifangda is optimistic about pharmaceutical stocks?

Fund companies have rare cases of "holding cards" listed companies. Recently, the Nuoan Fund "holding" A shares Zhuo Shengwei has caused discussions. According to the regulations of A shares, the Noon Growth Fund must not only fulfill the information disclosure obligation after the license is reached, but also cannot sell stocks within 6 months after the license.

Chi Yunfei, a senior analyst at the Shanghai Securities Fund Evaluation and Research Center, analyzes the Sino -Singapore Jingwei. Public funds choose to increase their holdings of pharmaceutical stocks. Some fund managers may be more optimistic about this stock, which has led to an increase in the overall shareholding. On the whole, the current valuation of pharmaceutical stocks is much cheaper than in the past. The pharmaceutical industry is an industry with long -term prospects. It does not rule out the possibility of some stock managers concentrated on the position.

As far as Haijia Medical is concerned, its performance has increased significantly in recent years. In the first half of 2022, the company achieved operating income of 1.526 billion yuan, an increase of 63.8%year -on -year, and a net profit of 228 million yuan, an increase of 11.2%year -on -year. Chen Hao grew up in the 2022 Interim Report in the Ichida Stock Connect that in the first half of 2022, affected by uncertain factors such as overseas interest rate hikes, repeated epidemics, and international situations, the Hong Kong stock market was relatively low. Among them, they further optimized and concentrated in the group, especially when the market panicity fell in mid -late March, firmly increased the high -quality companies in the Internet and medical services industries, and gradually replaced the value stocks of partial stable income to the value stocks with a stable income. Growth stocks with greater elasticity. However, Chi Yunfei reminded: "Investors cannot judge that a certain stock or an industry will have better performance in the future based on the fund increasing holdings or heavy positions."

The fund's "holding" listed companies is often regarded as a "double -edged sword" by the industry. For example, if the fund products have large -scale redemption, the fund manager will have to sell heavy stocks in a short time. Chi Yunfei said: "For large shareholders who hold high shares, there will be restrictions on holdings, but the judgment of major shareholders does not follow the fund company, but is calculated according to fund products. If a certain company's stock accounts for more than 5%of the total share capital, it may face the question of how to properly arrange the exit rhythm. "

From the end of the second quarter of 2022, the data of Haijia Medical equity held by the products held by the Funda Fund products speculated that the shareholding ratio of a single product was not high. At the end of the second quarter, the proportion of Yifangda Blue Chips held 0.39%of the net asset value of Haijia Medical equity; the proportion of the growth of the Ichida Hong Kong Stock Connect was slightly higher, reaching 6.92%. Weighing stocks. (For more report clues, please contact the author [email protected]) (Zhongxin Jingwei APP)

(The views in the article are for reference only, do not constitute investment suggestions, have risks in investment, and need to be cautious to enter the market.)

Editor in charge: Chang Tao

Pay attention to the official WeChat public account of JWVIEW (JWVIEW) to get more elite financial information.

- END -